Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Acta Vet Hung ; 71(3-4): 219-222, 2024 Jan 09.
Article in English | MEDLINE | ID: mdl-38193983

ABSTRACT

This study examined the effects of ergothioneine (EGT) supplementation as an antioxidant on the quality of boar spermatozoa when using liquid and frozen preservation methods. In the first experiment, boar semen was preserved in an extender supplemented with 0, 50, 100 and 200 µM EGT, at 15 °C, part of the samples for one and another part for three weeks. In comparison with the control (without EGT), EGT supplementation at 100 µM significantly increased the percentage of total motility of spermatozoa that were preserved as a liquid both for one and three weeks (P < 0.05). EGT supplementation did not affect the quality of preserved spermatozoa, irrespective of the EGT concentration. In the second experiment, semen was frozen and thawed in the freezing extender supplemented with 0, 50, 100 and 200 µM EGT. In comparison with the control, the 100 µM EGT supplementation significantly increased the percentages of total and progressive motility of frozen-thawed spermatozoa (P < 0.05). EGT (100 µM) supplementation did not affect the viability, the plasma membrane integrity, or the acrosomal integrity of frozen-thawed spermatozoa. These findings indicate that supplementing extenders with 100 µM EGT may improve the motility of boar sperm in both liquid and freezing preservation methods.


Subject(s)
Ergothioneine , Male , Swine , Animals , Ergothioneine/pharmacology , Semen , Dietary Supplements , Antioxidants/pharmacology , Spermatozoa
2.
Int J Med Mushrooms ; 24(2): 63-74, 2022.
Article in English | MEDLINE | ID: mdl-35446523

ABSTRACT

Pleurotus ostreatus (PO) and Hericium erinaceus (HE) have been traditionally used to treat various diseases, owing to their antioxidant, antimicrobial, neuroprotective, and antitumor effects. However, few studies have been reported on their antiaging effects. In this study, the antioxidant and antiaging activities of PO and HE aqueous extracts were investigated in ultraviolet A (UVA)-induced human dermal fibroblast cells (HDFs). The antioxidant properties of PO and HE aqueous extracts were measured by total polyphenol and ergothioneine content, and their antioxidant activity was analyzed with the 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) radical-scavenging assays. To demonstrate the antiaging effect of PO and HE aqueous extracts in UVA-induced HDFs, the secretion and mRNA expression of matrix metalloproteinase-1 (MMP-1), procollagen type I (PC1), and elastase were assessed by enzyme-linked immunosorbent assay (ELISA) and real-time PCR, respectively. The total polyphenol content in each extract was 13.6 and 11.7 mg gallic acid equivalents/g dry weight (DW), respectively, and the total ergothioneine content in each extract was 3.43 and 2.18 mg/g DW, respectively. The PO and HE extracts increased DPPH and ABTS radical-scavenging activity in a dose-dependent manner. In UVA-damaged HDFs, the extracts increased PC1 production but decreased MMP-1 production and elastase-1 activity. Furthermore, the mRNA levels of PC1, MMP-1, and elastase were recovered in the PO- and HE-treated UVA-irradiated HDFs compared to those in the irradiated control group. PO and HE aqueous extracts may be potentially used as a promising antiphotoaging agent.


Subject(s)
Ergothioneine , Pleurotus , Antioxidants/chemistry , Ergothioneine/metabolism , Ergothioneine/pharmacology , Fibroblasts/metabolism , Hericium , Humans , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 1/pharmacology , Pancreatic Elastase , Plant Extracts/chemistry , Pleurotus/metabolism , Polyphenols/pharmacology , RNA, Messenger
3.
Nutrients ; 14(6)2022 Mar 11.
Article in English | MEDLINE | ID: mdl-35334834

ABSTRACT

Phenotypic frailty is characterized by a progressive decline in physical functioning. During ageing, morphological and functional alterations involve the brain, and chief theories involve oxidative stress, free radical accumulation, and reduced antioxidant defenses as the most implicated mechanisms. From boosting the immune system to fighting senescence, medicinal mushrooms have been found to have a number of health and longevity benefits. Among them, Hericium erinaceus (He) has been demonstrated to display a variety of physiological effects, including anti-aging properties. Thus, He represents an attractive natural source for developing novel medicines and functional foods, based on the identification of its active ingredients and metabolites. Particularly, H. erinaceus primordium (He2) extract contains a high amount of Ergothioneine (ERGO), the longevity vitamin. Herein, we revealed the preventive effect of ERGO-rich He2 extract in a preclinical model, focusing on locomotor decline during ageing monitored through spontaneous behavioral test. This effect was accompanied by a significant decrease in some oxidative stress markers (NOS2, COX2) paralleled by an increase in P53, showed in cerebellar cortex cells and fibres by immunohistochemistry. In summary, we demonstrated the neuro-protective and preventive effects of He2 extract during aging, probably due to its peculiarly high ERGO content.


Subject(s)
Ergothioneine , Longevity , Ergothioneine/pharmacology , Hericium , Vitamins/pharmacology
4.
Antioxid Redox Signal ; 36(16-18): 1306-1317, 2022 06.
Article in English | MEDLINE | ID: mdl-34619979

ABSTRACT

Significance: Ergothioneine (ET) is an unusual sulfur-containing amino acid derived from histidine, acquired predominantly from food. Its depletion is associated with deleterious consequences in response to stress stimuli in cell culture models, prompting us to classify it as a vitamin in 2010, which was later supported by in vivo studies. ET is obtained from a variety of foods and is taken up by a selective transporter. ET possesses antioxidant and anti-inflammatory properties that confer cytoprotection. ET crosses the blood-brain barrier and has been reported to have beneficial effects in the brain. In this study, we discuss the cytoprotective and neuroprotective properties of ET, which may be harnessed for combating neurodegeneration and decline during aging. Recent Advances: The designation of ET as a stress vitamin is gaining momentum, opening a new field of investigation involving small molecules that are essential for optimal physiological functioning and maintenance of health span. Critical Issues: Although ET was discovered more than a century ago, its physiological functions are still being elucidated, especially in the brain. As ET is present in most foods, toxicity associated with its deprivation has been difficult to assess. Future Directions: Using genetically engineered cells and mice, it may now be possible to elucidate roles of ET. This coupled with advances in genomics and metabolomics may lead to identification of ET function. As ET is a stable antioxidant with anti-inflammatory properties, whose levels decline during aging, supplementing ET in the diet or consuming an ET-rich diet may prove beneficial. Antioxid. Redox Signal. 36, 1306-1317.


Subject(s)
Ergothioneine , Aging , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Cytoprotection , Ergothioneine/metabolism , Ergothioneine/pharmacology , Mice , Oxidative Stress , Vitamins
5.
Int J Mol Sci ; 22(6)2021 Mar 23.
Article in English | MEDLINE | ID: mdl-33806754

ABSTRACT

Medicinal use of mushrooms has been documented since ancient times, and in the modern world, mushrooms have a longstanding history of use in Eastern medicine. Recent interest in plant-based diets in Westernized countries has brought increasing attention to the use of mushrooms and mushroom-derived compounds in the prevention and treatment of chronic diseases. Edible mushrooms are the most abundant food sources of the modified amino acid, ergothioneine. This compound has been shown to accumulate in almost all cells and tissues, but preferentially in those exposed to oxidative stress and injury. The demonstrated cytoprotectant effect of ergothioneine has led many to suggest a potential therapeutic role for this compound in chronic conditions that involve ongoing oxidative stress and inflammation, including cardiovascular and metabolic diseases. However, the in vivo effects of ergothioneine and its underlying therapeutic mechanisms in the whole organism are not as clear. Moreover, there are no well-defined, clinical prevention and intervention trials of ergothioneine in chronic disease. This review highlights the cellular and molecular mechanisms of action of ergothioneine and its potential as a Traditional, Complementary and Alternative Medicine for the promotion of cardiometabolic health and the management of the most common manifestations of cardiometabolic disease.


Subject(s)
Agaricales/chemistry , Biological Products/pharmacology , Energy Metabolism/drug effects , Ergothioneine/pharmacology , Heart/drug effects , Myocardium/metabolism , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Antioxidants/chemistry , Antioxidants/pharmacology , Biological Products/chemistry , Dietary Supplements , Ergothioneine/chemistry , Humans
6.
Neuromolecular Med ; 23(1): 184-198, 2021 03.
Article in English | MEDLINE | ID: mdl-33067719

ABSTRACT

Ergothioneine (ET) is a naturally occurring antioxidant that is synthesized by non-yeast fungi and certain bacteria. ET is not synthesized by animals, including humans, but is avidly taken up from the diet, especially from mushrooms. In the current study, we elucidated the effect of ET on the hCMEC/D3 human brain endothelial cell line. Endothelial cells are exposed to high levels of the cholesterol oxidation product, 7-ketocholesterol (7KC), in patients with cardiovascular disease and diabetes, and this process is thought to mediate pathological inflammation. 7KC induces a dose-dependent loss of cell viability and an increase in apoptosis and necrosis in the endothelial cells. A relocalization of the tight junction proteins, zonula occludens-1 (ZO-1) and claudin-5, towards the nucleus of the cells was also observed. These effects were significantly attenuated by ET. In addition, 7KC induces marked increases in the mRNA expression of pro-inflammatory cytokines, IL-1ß IL-6, IL-8, TNF-α and cyclooxygenase-2 (COX2), as well as COX2 enzymatic activity, and these were significantly reduced by ET. Moreover, the cytoprotective and anti-inflammatory effects of ET were significantly reduced by co-incubation with an inhibitor of the ET transporter, OCTN1 (VHCL). This shows that ET needs to enter the endothelial cells to have a protective effect and is unlikely to act via extracellular neutralizing of 7KC. The protective effect on inflammation in brain endothelial cells suggests that ET might be useful as a nutraceutical for the prevention or management of neurovascular diseases, such as stroke and vascular dementia. Moreover, the ability of ET to cross the blood-brain barrier could point to its usefulness in combatting 7KC that is produced in the CNS during neuroinflammation, e.g. after excitotoxicity, in chronic neurodegenerative diseases, and possibly COVID-19-related neurologic complications.


Subject(s)
Antioxidants/pharmacology , COVID-19/complications , Endothelial Cells/drug effects , Ergothioneine/pharmacology , Ketocholesterols/toxicity , Nervous System Diseases/prevention & control , Neuroprotective Agents/pharmacology , Antioxidants/pharmacokinetics , Apoptosis/drug effects , Biological Transport , Blood-Brain Barrier , Brain/blood supply , Brain/cytology , Cell Line , Cholesterol/metabolism , Claudin-5 , Cyclooxygenase 2/biosynthesis , Cyclooxygenase 2/genetics , Cytokines/biosynthesis , Cytokines/genetics , Drug Evaluation, Preclinical , Ergothioneine/pharmacokinetics , Humans , Microvessels/cytology , Nervous System Diseases/etiology , Neuroprotective Agents/pharmacokinetics , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type III/metabolism , Organic Cation Transport Proteins , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Symporters , Zonula Occludens-1 Protein
7.
J Nutr Biochem ; 84: 108453, 2020 10.
Article in English | MEDLINE | ID: mdl-32653808

ABSTRACT

There is evidence from both in vitro and animal models that the consumption of edible mushrooms has beneficial effects on health. It is unclear whether similar effects exist in humans and which bioactive compounds are present. This review synthesises the evidence on the world's most commonly consumed mushroom, Agaricus bisporus to (i) examine its effect on human health outcomes; and (ii) determine the nutrient density of its bioactive compounds, which may explain their health effects. A systematic literature search was conducted on the consumption of A. bisporus, without date and study design limits. Bioactive compounds included ergosterol, ergothioneine, flavonoids, glucans and chitin. Two authors independently identified studies for inclusion and assessed methodological quality. Beneficial effects of A. bisporus on metabolic syndrome, immune function, gastrointestinal health and cancer, with the strongest evidence for the improvement in Vitamin D status in humans, were found. Ultraviolet B (UVB) exposed mushrooms may increase and maintain serum 25(OH)D levels to a similar degree as vitamin D supplements. A. bisporus contain beta-glucans, ergosterol, ergothioneine, vitamin D and an antioxidant compound usually reported as flavonoids; with varying concentrations depending on the type of mushroom, cooking method and duration, and UVB exposure. Further research is required to fully elucidate the bioactive compounds in mushrooms using vigorous analytical methods and expand the immunological markers being tested. To enable findings to be adopted into clinical practice and public health initiatives, replication of existing studies in different population groups is required to confirm the impact of A. bisporus on human health.


Subject(s)
Agaricus , Biological Products/pharmacology , Agaricus/chemistry , Animals , Biological Products/chemistry , Biological Products/therapeutic use , Ergosterol/chemistry , Ergosterol/pharmacology , Ergosterol/therapeutic use , Ergothioneine/chemistry , Ergothioneine/pharmacology , Ergothioneine/therapeutic use , Flavonoids/chemistry , Flavonoids/pharmacology , Flavonoids/therapeutic use , Glucans/chemistry , Glucans/pharmacology , Glucans/therapeutic use , Humans
8.
Oxid Med Cell Longev ; 2020: 2576823, 2020.
Article in English | MEDLINE | ID: mdl-32104530

ABSTRACT

UVA irradiation induced ROS-mediated photo damage to the human skin leading to coarseness, wrinkling, pigmentation, and cutaneous malignancies. We investigated the dermatoprotective efficacies of submicromolar concentrations of ergothioneine (EGT, 0.125-0.5 µM), which occurs naturally as a sulfur-containing amino acid, in the mechanisms in human skin fibroblast (HSF) cells. UVA-induced AP-1 (c-Fos and c-Jun) translocation was found to be inhibited by EGT treatments with the parallel inhibition of the collagenolytic matrix metalloproteinase- (MMP-) 1 activation and type I procollagen degradation. Moreover, EGT mitigated UVA-induced ROS generation. An increase in the amount of antioxidant genes (HO-1, NQO-1, and γ-GCLC) from EGT and were associated with upregulated Nrf2 expressions in a dose-dependent or time-dependent manner. We confirmed this from Nrf2 translocation and increased nuclear ARE promoter activity that underlie EGT dermatoprotective activities. Also, glutathione (GSH) levels (from γ-GCLC) were significantly increased. Moreover, we showed that mediated by ERK, JNK, and PKC, signaling cascades mediate Nrf2 translocation. We confirmed this phenomenon by the suppressed nuclear Nrf2 activation in cells that were treated with respective inhibitors (PD98059, SP600125, and GF109203X). However, antioxidant protein expressions were impaired in Nrf2 knockdown cells to confirm that ARE/Nrf2 pathways and the inhibition of AP-1 had significant roles in EGT-mediated protective effects. We can conclude that ergothioneine ameliorated UVA-induced skin aging and is a useful food supplement for skin care products.


Subject(s)
Ergothioneine/pharmacology , Fibroblasts/drug effects , NF-E2-Related Factor 2/metabolism , Signal Transduction/drug effects , Skin Aging/drug effects , Transcription Factor AP-1/metabolism , Antioxidants/pharmacology , Cell Line , Fibroblasts/cytology , Fibroblasts/metabolism , Fibroblasts/radiation effects , Glutathione/metabolism , Heme Oxygenase-1/metabolism , Humans , MAP Kinase Signaling System/drug effects , NAD(P)H Dehydrogenase (Quinone)/metabolism , NF-E2-Related Factor 2/genetics , Procollagen/metabolism , Protein Kinase C/metabolism , RNA, Small Interfering , Reactive Oxygen Species/metabolism , Reactive Oxygen Species/radiation effects , Signal Transduction/genetics , Transcription Factor AP-1/antagonists & inhibitors , Ultraviolet Rays , Up-Regulation/drug effects
9.
Nutr Res Rev ; 33(2): 190-217, 2020 12.
Article in English | MEDLINE | ID: mdl-32051057

ABSTRACT

Ergothioneine (ERG) is an unusual thio-histidine betaine amino acid that has potent antioxidant activities. It is synthesised by a variety of microbes, especially fungi (including in mushroom fruiting bodies) and actinobacteria, but is not synthesised by plants and animals who acquire it via the soil and their diet, respectively. Animals have evolved a highly selective transporter for it, known as solute carrier family 22, member 4 (SLC22A4) in humans, signifying its importance, and ERG may even have the status of a vitamin. ERG accumulates differentially in various tissues, according to their expression of SLC22A4, favouring those such as erythrocytes that may be subject to oxidative stress. Mushroom or ERG consumption seems to provide significant prevention against oxidative stress in a large variety of systems. ERG seems to have strong cytoprotective status, and its concentration is lowered in a number of chronic inflammatory diseases. It has been passed as safe by regulatory agencies, and may have value as a nutraceutical and antioxidant more generally.


Subject(s)
Antioxidants/pharmacology , Biological Products/pharmacology , Dietary Supplements , Ergothioneine/pharmacology , Oxidative Stress/drug effects , Actinobacteria/chemistry , Animals , Fungi/chemistry , Humans , Organic Cation Transport Proteins/metabolism , Symporters/metabolism
10.
Hypertension ; 75(2): 561-568, 2020 02.
Article in English | MEDLINE | ID: mdl-31865793

ABSTRACT

Preeclampsia is a multifactorial hypertensive disorder of pregnancy founded on abnormal placentation, and the resultant placental ischemic microenvironment is thought to play a crucial role in its pathophysiology. Placental ischemia because of fluctuations in the delivery of oxygen results in oxidative stress, and recent evidence suggests that mitochondrial dysfunction may be a prime mediator. However, large clinical trials of therapeutic antioxidants such as vitamins C and E for the treatment of preeclampsia have been disappointing. L-(+)-ergothioneine (ERG)-an unusual amino acid betaine derived from histidine-has important cytoprotective and antioxidant properties under conditions of high oxidative stress. In this study, we investigated the potential therapeutic effects of administration of ERG in the reduced uterine perfusion pressure (RUPP) rat model of preeclampsia. ERG (25 mg/kg per day) was administered to rats on gestational day 11. On gestational day 14, RUPP surgery was performed, and on gestational day 19, blood pressure (mean arterial pressure) and fetal growth were measured. Production of mitochondria-specific H2O2 was analyzed in vivo in kidney samples. ERG ameliorated the hypertension (129±3 versus 115±4 mm Hg; P=0.01; n=8) and significantly increased pup weight in RUPP rats. ERG also significantly decreased circulating levels of antiangiogenic sFlt-1 (soluble fms-like tyrosine kinase-1) in RUPP rats (1367±245 pg/mL; P=0.04). Mitochondria-specific H2O2 (0.022±0.003 versus 0.029±0.001; MitoP/B ratio, n=3; P=0.05) was also significantly decreased in kidney tissue in RUPP rats treated with ERG. These data support the potential use of ERG for the treatment of preeclampsia.


Subject(s)
Ergothioneine/pharmacology , Pre-Eclampsia/drug therapy , Pregnancy, Animal , Regional Blood Flow/drug effects , Uterus/blood supply , Animals , Antioxidants/pharmacology , Biomarkers/blood , Biomarkers/urine , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Female , Pre-Eclampsia/metabolism , Pre-Eclampsia/physiopathology , Pregnancy , Rats , Rats, Sprague-Dawley , Uterus/physiopathology , Vascular Endothelial Growth Factor Receptor-1/metabolism
11.
Int J Med Mushrooms ; 19(9): 777-495, 2017.
Article in English | MEDLINE | ID: mdl-29199553

ABSTRACT

Because of the high incidence of and high mortality rates associated with cancer, effective therapy for cancer is currently an imperative issue. Taiwanofungus salmoneus, a medicinal mushroom indigenous to Taiwan, has been demonstrated to exhibit various physiological activities and harmless effects. The bioactive compounds and anticancer abilities of T. salmoneus mycelia and fermented products were evaluated in this study. Total phenols, flavonoids, and ergothioneine were detected in mycelia and fermented products, and the amount of ergothioneine was evaluated in buckwheat (56.25-118.64 µg/g extract) and oats (53.60-138.70 µg/g extract) after fermentation. Results showed that T. salmoneus-fermented buckwheat and oats exhibited better apoptotic effects on Sk-Hep-1 and Caco-2 cells than sorafenib and celecoxib via receptor-linked apoptosis and mitochondria-mediated apoptosis. In addition, T. salmoneus-fermented buckwheat may have potential for replacing anticancer drugs or for consumption as a dietary supplement to retard cancer development.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Avena , Fagopyrum , Mycelium/chemistry , Polyporales/chemistry , Caco-2 Cells , Ergothioneine/pharmacology , Fermentation , Flavonoids/pharmacology , Humans , Phenols/pharmacology , Taiwan
12.
Brain Behav ; 6(6): e00477, 2016 06.
Article in English | MEDLINE | ID: mdl-27134772

ABSTRACT

BACKGROUND: Clinically used antidepressants suffer from various side effects. Therefore, we searched for a safe antidepressant with minimal side effects among food ingredients that are distributed to the brain. Here, we focused on ERGO (ergothioneine), which is a hydrophilic antioxidant and contained at high levels in edible golden oyster mushrooms. ERGO is a typical substrate of carnitine/organic cation transporter OCTN1/SLC22A4, which is expressed in the brain and neuronal stem cells, although little is known about its permeation through the BBB (blood-brain barrier) or its neurological activity. METHODS: To clarify the exposure of ERGO to brain and the possible antidepressant-like effect after oral ingestion, ERGO or GOME (golden oyster mushroom extract) which contains 1.2% (w/w) ERGO was mixed with feed and provided to mice for 2 weeks, and then ERGO concentration and antidepressant-like effect were evaluated by LC-MS/MS and FST (forced swimming test) or TST (tail suspension test), respectively. RESULTS: Diet containing ERGO or GOME greatly increased the ERGO concentrations in plasma and brain, and significantly decreased the immobility time in both FST and TST. The required amount of GOME (~37 mg/day) to show the antidepressant-like effect corresponds to at most 8 g/day in humans. In mice receiving GOME-containing diet, doublecortin-positive cells showed a significant increase from the basal level, suggesting promotion of neuronal differentiation. CONCLUSION: Thus, orally ingested ERGO is transported across the BBB into the brain, where it may promote neuronal differentiation and alleviate symptoms of depression at plausibly achieved level of daily ingestion.


Subject(s)
Antidepressive Agents/pharmacology , Antioxidants/pharmacology , Behavior, Animal/drug effects , Brain/metabolism , Ergothioneine/pharmacology , Plant Extracts/pharmacology , Pleurotus , Animals , Antidepressive Agents/administration & dosage , Antidepressive Agents/blood , Antioxidants/administration & dosage , Antioxidants/metabolism , Brain/drug effects , Depression/diet therapy , Depression/drug therapy , Ergothioneine/administration & dosage , Ergothioneine/blood , Male , Mice , Mice, Inbred C57BL , Plant Extracts/administration & dosage , Plant Extracts/blood
13.
Cryobiology ; 69(1): 68-73, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24854868

ABSTRACT

The aim of this study was to evaluate the effects of ergothioneine and cysteamine as antioxidant supplements in a soybean lecithin extender for freezing ram semen. Twenty-four ejaculates were collected from four rams and diluted with extenders (1.5% soybean lecithin, 7% glycerol) containing no supplements (control) and cysteamine or ergothioneine (2, 4, 6 or 8mM). Motility by CASA, viability, plasma membrane functionality (HOS test), total abnormality, lipid peroxidation, glutathione peroxidase (GPx) activity and capacitation status (CTC staining) were assessed after thawing. Using 6mM of either antioxidant improved total motility. Cysteamine at 6mM and ergothioneine at 4 and 6mM improved viability and reduced lipid peroxidation (malondialdehyde concentration). Both antioxidants improved membrane functionality significantly, except at 8mM. Progressive motility, kinematic parameters, GPx activity, capacitation status and sperm abnormalities were not influenced by the antioxidant supplements. In conclusion, cysteamine at 6mM and ergothioneine at 4 or 6mM seem to improve the post-thawing quality of ram semen cryopreserved in a soybean lecithin extender.


Subject(s)
Cryoprotective Agents/pharmacology , Cysteamine/pharmacology , Ergothioneine/pharmacology , Plant Lectins/pharmacology , Soybean Proteins/pharmacology , Spermatozoa/drug effects , Animals , Antioxidants/pharmacology , Cell Survival/drug effects , Cryopreservation , Glutathione Peroxidase , Lipid Peroxidation/drug effects , Male , Oxidative Stress/drug effects , Semen/drug effects , Semen Analysis , Semen Preservation , Sheep , Sperm Motility/drug effects
14.
Free Radic Res ; 48(9): 1049-60, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24797165

ABSTRACT

Male C57BL/6J mice treated with D-galactose (DG) were used to examine the effects of ergothioneine (EGT), melatonin (MEL), or their combination (EGT+MEL) on learning and memory abilities. The mice were divided into five groups and injected subcutaneously with DG (0.3 mL of 1% DG/mouse) except for group 1 (normal controls). Group 3 was orally supplemented with EGT [0.5 mg/kg body weight (bw)], group 4 with MEL (10 mg/kg bw, p.o.), and group 5 with EGT+MEL. EGT and MEL were provided daily for 88 days, while DG was provided between days 7 to 56. Active avoidance task and Morris water-maze task were used to evaluate learning and memory abilities. DG treatment markedly increased escape latency and decreased the number of avoidance in the active avoidance test, whereas EGT and MEL alone significantly improved the performance. DG also impaired the learning and memory abilities in the water-maze task, and EGT and MEL alone also significantly improved the performance. EGT+MEL produced the strongest effects in both tasks. EGT and MEL alone markedly decreased ß-amyloid protein accumulation in the hippocampus and significantly inhibited lipid peroxidation and maintained glutathione/glutathione disulfide ratio and superoxide dismutase activity in brain tissues of DG-treated mice. MEL alone completely prevented the rise in brain acetylcholine esterase activity induced by DG, whereas EGT and EGT+MEL were only partially effective. Overall, EGT, MEL, and, in particular, the combination of EGT and MEL effectively protect against learning and memory deficits in C57BL/6J mice treated with DG, possibly through attenuation of oxidative damage.


Subject(s)
Antioxidants/pharmacology , Brain/drug effects , Ergothioneine/pharmacology , Melatonin/pharmacology , Alzheimer Disease/metabolism , Animals , Brain/metabolism , Brain/pathology , Chromatography, High Pressure Liquid , Disease Models, Animal , Galactose/toxicity , Immunohistochemistry , Male , Maze Learning/drug effects , Memory/drug effects , Memory Disorders/chemically induced , Mice , Mice, Inbred C57BL , Oxidative Stress/drug effects
15.
Int J Med Mushrooms ; 15(3): 267-75, 2013.
Article in English | MEDLINE | ID: mdl-23662614

ABSTRACT

The culinary-medicinal king oyster mushroom Pleurotus eryngii is known to contain ergothioneine, and its products, including fruiting bodies, mycelia, and solid-state fermented products (adlay and buckwheat), were prepared to study their antioxidant properties. Fruiting bodies, regular and Hi-Ergo mycelia, and fermented products contained 2.05, 1.68, 5.76, 0.79-0.80 mg/g of ergothioneine, respectively. On the basis of the results obtained, P. eryngii products had effective antioxidant activity, reducing power, and scavenging ability on 1,1-diphenyl-2-picrylhydrazyl radicals and chelating ability on ferrous ions. Hi-Ergo mycelia was the most effective in the first 3 antioxidant properties in addition to its ergothioneine content. In addition, fruiting bodies were more effective in all antioxidant properties than regular mycelia. For ethanolic and hot water extracts from mycelia and fruiting bodies, the correlation coefficients between total phenol contents and each antioxidant attribute were 0.483-0.921. Overall, P. eryngii products with high amounts of ergothioneine could be used beneficially as a functional food.


Subject(s)
Agaricales/chemistry , Antioxidants/metabolism , Ergothioneine/metabolism , Ergothioneine/pharmacology , Mycelium/chemistry , Pleurotus/chemistry , Antioxidants/chemistry , Ergothioneine/chemistry , Fermentation , Pleurotus/metabolism
16.
Cryobiology ; 63(1): 1-6, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21513707

ABSTRACT

The aim of the current study was to evaluate the effects of cysteine and ergothioneine on the post-thawed sperm parameters, lipid peroxidation and antioxidant activities. Semen samples from 5 mature Merino rams were used in the study. Semen samples, which were diluted with a Tris-based extender containing l-Cysteine and l-(+)-Ergothioneine and no antioxidant (control), were cooled to 5°C and frozen in 0.25 ml French straws. Frozen straws were then thawed individually at 37°C for 20s in a water bath for evaluation. Ergothioneine at doses of 2 and 4mM increased percentages of subjective motility, VSL and VCL, compared to controls following the freeze-thawing (P<0.001). Ergothioneine at three different doses led to higher rates of progressive motility and VAP, compared to control groups (P<0.001). Cysteine and ergothioneine at three doses provided the higher rates of ALH, in comparison to no antioxidant group (P<0.001). As regards CASA motility, supplementation with antioxidants did not provide any significant difference on the percentage of post-thaw sperm CASA motilities, in comparison to the control. In regards of sperm membrane integrity, only cysteine 1mM provided a greater protective effect, compared to control (P<0.001). Percentages of sperm with high mitochondrial activity were dramatically increased with cysteine at doses of 1 and 2mM, compared to control (P<0.05). No significant differences were observed in sperm acrosome integrities among groups. CAT activity was increased significantly only in cysteine1mM compared to control group (P<0.001). Cysteine at doses of 2 and 4mM showed a tendency of increased activities of CAT when compared to control. But these increases were not statistically significant. Supplementation with antioxidants did not significantly affect activities of SOD and GPx. Findings of this study showed that ergothioneine supplementation in semen extenders, was of greater benefit to motility and motion characteristics of frozen-thawed ram sperm.


Subject(s)
Antioxidants/pharmacology , Cysteine/pharmacology , Ergothioneine/pharmacology , Spermatozoa/drug effects , Animals , Catalase/metabolism , Cryoprotective Agents/pharmacology , Glutathione Peroxidase/metabolism , Male , Semen Preservation , Sheep , Sperm Motility/drug effects , Superoxide Dismutase/metabolism
17.
Biofactors ; 27(1-4): 157-65, 2006.
Article in English | MEDLINE | ID: mdl-17012772

ABSTRACT

The "Long Terminal Repeat" (LTR) of HIV-1 is the target of cellular transcription factors such as NF-kappaB, and serves as the promoter-enhancer for the viral genome when integrated in host DNA. Various LTR-reporter gene constructs have been used for in vitro studies of activators or inhibitors of HIV-1 transcription, e.g., to show that antioxidants such as lipoic acid and selenium inhibit NF-kappaB-dependent HIV-1 LTR activation. One such construct is the pHIVlacZ plasmid, with the HIV-1 LTR driving expression of the lacZ gene (encoding beta-galactosidase, beta-gal). Typically, for inhibitor screening, cells transfected with pHIVlacZ are activated using tumor necrosis factor-alpha (TNF-alpha), and the colorimetric o-nitrophenol assay is used to assess changes in beta-gal activity. A variant of this assay was developed as described here, in which LTR activation was induced by pro-fs, a novel HIV-1 gene product encoded via a -1 frameshift from the protease gene. Cotransfection of cells with pHIVlacZ along with a pro-fs construct produced a significant increase in beta-gal activity over controls. L-ergothioneine dose dependently inhibited both TNF-alpha-mediated and pro-fs-mediated increases in beta-gal activity, with an IC50 of about 6 mM. Thus antioxidant strategy involving ergothioneine derived from food plants might be of benefit in chronic immunodeficiency diseases.


Subject(s)
Antioxidants/pharmacology , Ergothioneine/pharmacology , HIV/drug effects , Animals , Cell Line , Dietary Supplements , Dose-Response Relationship, Drug , Gene Expression Regulation, Viral/drug effects , Genes, Reporter/genetics , Genes, Viral/genetics , Genetic Vectors/genetics , HIV/genetics , HIV/metabolism , HIV Long Terminal Repeat/genetics , Humans , NF-kappa B/metabolism , Transcription, Genetic/genetics , Transcriptional Activation/drug effects , Transfection , Tumor Necrosis Factor-alpha/metabolism
18.
Phytother Res ; 18(11): 877-83, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15597303

ABSTRACT

The interaction of geshoidin, diospyrin and ergothioneine, with heterologously expressed human glutathione transferases (GSTs) was investigated in vitro. Diospyrin and geshoidin inhibited the three GST isoforms tested, with IC50 values in the range 0.1-0.5 microm, whereas ergothioneine had no effect on the GSTs. The predominant mode of inhibition was noncompetitive with respect to both glutathione (GSH) and 1-chloro-2,4-dinitrobenzene (CDNB). Diospyrin, however, competitively inhibited A1-1 and M1-1 with respect to GSH and geshoidin displayed mixed inhibition toward A1-1 with respect to GSH. The Ki values for diospyrin with respect to both GSH and CDNB were in the range 0.08-0.6 microM and those for geshoidin were in the range 16-173 microM. These results indicate that diospyrin is a potent inhibitor of heterologously expressed human GSTs A1-1, M1-1 and P1-1. Diospyrin and geshoidin were also found to inactivate P1-1 with diospyrin being a potent inactivator. Given these inhibitory properties, diospyrin may be a potential GST chemomodulator. Ergothioneine inactivated P1-1 only after preincubation and it enhanced ethacrynic acid inactivation of P1-1. Inactivation of P1-1 by ergothioneine may have implications for the antioxidant roles of P1-1 and ergothioneine in vivo.


Subject(s)
Enzyme Inhibitors/pharmacology , Glucosides/pharmacology , Glutathione Transferase/drug effects , Naphthalenes/pharmacology , Phytotherapy , Plants, Medicinal , Dose-Response Relationship, Drug , Drug Interactions , Ergothioneine/pharmacology , Glutathione Transferase/antagonists & inhibitors , Humans , Inhibitory Concentration 50 , Naphthoquinones/pharmacology
19.
Clin Nutr ; 23(2): 183-93, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15030958

ABSTRACT

BACKGROUND & AIMS: L-ergothioneine is a fungal metabolite exhibiting antioxidant functions in cells. The aim of this study was to assess the effect of oral administration of L-ergothioneine on the oxidative damage in vivo caused by the Fenton reagent ferric-nitrilotriacetate. METHODS: Rats were supplemented with L-ergo prior to the administration of acute dose of ferric-nitrilotriacetate. Kidney and liver levels of L-ergothioneine, glutathione, alpha-tocopherol, polyunsaturated fatty acids and conjugated dienes were assessed. RESULTS: Oral administration of 70 mg L-ergo/kg body weight of rats for 7 days prior to the injection of ferric-nitrilotriacetate protected the fatty acids against oxidation, with notable protections directed to: 20:5 (eicosapentaenoic acid) (23%), 22:6 (docosahexaenoinic acid) (30%), 20:3 n6 (eicosatrienoic acid) (22%), 20:4 (arachidonic acid) (25%), 18:2 linoleic acid (25%) and 18:1 oleic acid (14%) in the kidney. The protection of 20:5, 20:3 n6 and 18:1 in the liver by 32%, 20% and 11%, respectively, were statistically significant. L-ergothioneine significantly reduced kidney and liver levels of conjugated dienes and conserved the concentrations of alpha-tocopherol and glutathione in the kidney and liver in the ferric-nitrilotriacetate/L-ergothioneine treated rats. CONCLUSION: Supplementation with L-ergothioneine not only protects the organs against the lipid peroxidation but conserves the consumption of endogenous glutathione and alpha-tocopherol. However consumption of mushrooms may have better promise as dietary sources of L-ergothioneine to humans.


Subject(s)
Antioxidants/pharmacology , Ergothioneine/pharmacology , Kidney/drug effects , Liver/drug effects , Nitrilotriacetic Acid/analogs & derivatives , Oxidative Stress/drug effects , Animals , Chromatography, High Pressure Liquid , Ergothioneine/analysis , Fatty Acids, Unsaturated/analysis , Ferric Compounds/administration & dosage , Glutathione/analysis , Kidney/chemistry , Lipids/analysis , Liver/chemistry , Male , Nitrilotriacetic Acid/administration & dosage , Oxidation-Reduction , Rats , Rats, Wistar , alpha-Tocopherol/analysis
20.
Food Chem Toxicol ; 40(12): 1751-5, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12419688

ABSTRACT

The natural antioxidant ergothioneine (2-mercaptohistidine trimethylbetaine) is a fungal metabolite and found in most plant and animal tissues. The effect of ergothioneine on diabetic embryopathy in rats was assessed. Supplementation of diabetic pregnant rats with L-ergothioneine (1.147 mg/kg body weight) daily for the first 11.5 days of pregnancy reduced the rate of embryo malformations, to values similar to the non-diabetic animals. The ergothioneine had no effect on the plasma glucose levels, both in diabetic and control animals. We conclude that the inhibition of the glucose-mediated free radical dependent embryo malformation by ergothioneine is an important antioxidant prophylactic mechanism, which when combined with vitamin E could benefit the management of diabetic embryopathy.


Subject(s)
Antioxidants/pharmacology , Congenital Abnormalities/prevention & control , Embryonic and Fetal Development/drug effects , Ergothioneine/pharmacology , Pregnancy in Diabetics/embryology , Animals , Antioxidants/administration & dosage , Blood Glucose/analysis , Diabetes Mellitus, Experimental , Ergothioneine/administration & dosage , Female , Neural Tube Defects/prevention & control , Pregnancy , Pregnancy Outcome , Pregnancy in Diabetics/drug therapy , Rats , Rats, Wistar , Vitamin E/administration & dosage , Vitamin E/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL